Enrish Pharmaceutical Private Limited - Due diligence report

A 360° intelligence report on Enrish Pharmaceutical Private Limited: trust score, financial health, credit view, compliance, directors, grow…

2016-05-07 Thane, Maharashtra Active Unlisted Active Compliant
Share
EP Enrish Pharmaceutical Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Enrish Pharmaceutical Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
77/100
Trust Score
Low Risk

Enrish Pharmaceutical Private Limited is assessed as Low Risk with a Trust Score of 77/100. Enrish Pharmaceutical Private Limited is an active private limited indian non-government company incorporated in 2016, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and moderate financial risk profile.

Report generated on 16 Jul 2026 from the latest processed filings. Enrish Pharmaceutical Private Limited snapshot & full profile →

Financial Health › Good
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
77/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
88/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
60/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
55/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
95/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
50/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 55/100 Moderate
  • Negative operating earnings - debt service depends on external support.
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 2 open (8.00 Lakh) · 0 satisfied (-).

Banking relationships (from registered charges)
LenderChargesAmount
Punjab And Maharashtra Co-Operative Bank Limited2 48.0 cr
Compliance Score: 88/100 Low Risk
  • Company status is Active as per MCA.
  • Balance sheet slightly behind (Mar 2024).
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 90/100
NameDIN / PANDesignationAppointedTenureDIN status
SUSHANT SUDHIR BALA 01234567 Director 01/04/2018 6 yrs Approved
VIJAYKUMAR SHANKARRAO MOON 01234567 Director 01/04/2018 6 yrs Approved
MANISHKUMAR GUNJESHNARI MISHRA 01234567 Director 01/04/2018 6 yrs Approved
SHRIKANT SUNDAR RANE 01234567 Director 01/04/2018 6 yrs Approved
  • 4 directors on the board.
  • No disqualified or deactivated DINs.
  • 3 director exit(s) in the last 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 95 · Distress 50
Growth signals & trust indicators
Revenue acceleration: +38% over 4 year(s).
Latest year revenue grew 1.42.
Profit expanded 2.1x year-on-year.
Asset base grew 24% - capacity expansion.
Net margin improved to 0.86.
Operating for 10+ years.
Active GST registration(s).
Distress signals & risk flags
Outside liabilities up 61% in a year.
Negative net worth.
3 director exits within 2 years.
2 open charge(s) registered - assets are encumbered.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence73/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 3 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment65/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 2 open charge(s) of 8.00 Lakh already registered.
  • Compliance record supports lending.
Investor view78/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 5 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 14 events
19 Jun 2025
Director ceased
SHRIKANT SUNDAR RANE
30 Sep 2024
Last AGM held
Annual general meeting
29 Sep 2024
Director ceased
SUSHANT SUDHIR BALA
Director ceased
VIJAYKUMAR SHANKARRAO MOON
31 Mar 2024
Latest balance sheet
Filed with ROC
03 Feb 2022
Director appointed
SUSHANT SUDHIR BALA (Director)
Director appointed
VIJAYKUMAR SHANKARRAO MOON (Director)
22 Mar 2021
Director ceased
ANIL PARMAL SINGH
28 Mar 2018
Charge created
Punjab And Maharashtra Co-Operative Bank Limited - 5.00 Lakh
30 Mar 2017
Charge created
Punjab And Maharashtra Co-Operative Bank Limited - 3.00 Lakh
01 Dec 2016
Director appointed
SHRIKANT SUNDAR RANE (Director)
Director ceased
DHARAMENDRA ASHOK MISHRA
07 May 2016
Incorporated
Registered with Roc Mumbai
Director appointed
MANISHKUMAR GUNJESHNARI MISHRA (Director)
10

Key Observations

Auto-generated from the data above
Revenue grew 38% over the last 4 financial year(s).
Net profit margin moved from 1.42 to 2.1x.
Compliance record is strong - status, filings and flags are clean.
4 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Brahmavar Chemicals Private Limited U24296KA1976PTC003032 Brahmavar, Karnataka, India
Kujeeva Chemicals Private Limited U24110MH1990PTC055683 Mumbai, Maharashtra, India
Colloids And Coagulants India Private Limited U02520TZ1989PTC002451 Coimbatore, Tamil Nadu, India
Nicera Industries Private Limited U02691TZ1993PTC004534 Erode, Tamil Nadu, India
Kvezal Healthcare Private Limited U51909GJ2021PTC125593 Kalol, Gujarat, India
Virani Pharma Private Limited U24232MH2010PTC210030 Bhayander East, Maharashtra, India
Sanozen Pharma Private Limited U24239TG2016PTC110123 Hyderabad, Telangana, India
Avyagra Ventures Private Limited U24100MP2019PTC049066 Ujjain, Madhya Pradesh, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Enrish Pharmaceutical Private Limited before audits and certifications: compliance score 88/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Enrish Pharmaceutical Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 55/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 95/100, margin trends, ownership structure and peer set for Enrish Pharmaceutical Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 77/100, distress signals and MSME payment-delay disclosures - know whether Enrish Pharmaceutical Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Enrish Pharmaceutical Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Enrish Pharmaceutical Private Limited an active company?

Enrish Pharmaceutical Private Limited has MCA status “Active” with a compliance score of 88/100 (Low Risk).

Is Enrish Pharmaceutical Private Limited financially healthy?

Enrish Pharmaceutical Private Limited has a Financial Health Score of 60/100 (Moderate) based on its filed financial statements.

Should I do business with Enrish Pharmaceutical Private Limited?

Its overall Trust Score is 77/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Enrish Pharmaceutical Private Limited?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 4 active director(s) are on record.

Does Enrish Pharmaceutical Private Limited have loans or charges against its assets?

2 open charge(s) are registered against its assets.

Is Enrish Pharmaceutical Private Limited up to date with its ROC filings?

Balance sheet slightly behind (Mar 2024). Overall compliance score: 88/100 (Low Risk).

Is it risky to lend to Enrish Pharmaceutical Private Limited?

Its Credit Risk Score is 55/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.